FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer

    NEXT STORY
    Ophthalmic Diagnostic Devices Market to Reach USD 3.86 Billion by 2026; Increasing Prevalence of Ocular Disorders to Boost Growth: Fortune Business Insights™
    PREV STORY
    Teleflex to Present at the Raymond James 41st Annual Institutional Investors Conference
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®

    Overall summary score was also significantly higher for Entresto patients than for patients not ...

    author_avatar
    NASDAQ Market News

    Oncology Pharma and Ribera Solutions Signed a Licensing Agreement for the Use of Ribera’s Clinical Trials Platform, Connect2Med

    author_avatar
    NASDAQ Market News

    Orion Corporation: Organising meeting of the Board of Directors

    ORION CORPORATION         STOCK EXCHANGE RELEASE 22 MARCH 2017 at 5.15 P.M. EET                      Orion Corporation: ...

    author_avatar
    NASDAQ Market News